 Gwendolyn Kerby
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tobacco Smoke Pollution | 7 | 2023 | 227 | 0.920 |
Why?
| | Cystic Fibrosis | 10 | 2018 | 1161 | 0.750 |
Why?
| | Respiratory Function Tests | 8 | 2015 | 544 | 0.700 |
Why?
| | Smoking Cessation | 4 | 2022 | 440 | 0.490 |
Why?
| | Pseudomonas Infections | 2 | 2018 | 230 | 0.420 |
Why?
| | Spirometry | 4 | 2012 | 233 | 0.400 |
Why?
| | Neuroendocrine Cells | 1 | 2012 | 33 | 0.370 |
Why?
| | Cough | 3 | 2013 | 124 | 0.370 |
Why?
| | Plethysmography | 4 | 2012 | 104 | 0.280 |
Why?
| | Lung | 4 | 2015 | 4106 | 0.270 |
Why?
| | Cotinine | 3 | 2021 | 77 | 0.240 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 664 | 0.230 |
Why?
| | Prednisone | 2 | 2019 | 224 | 0.200 |
Why?
| | Sodium Chloride | 2 | 2015 | 138 | 0.200 |
Why?
| | Child, Preschool | 13 | 2022 | 11853 | 0.200 |
Why?
| | Pediatricians | 1 | 2023 | 121 | 0.180 |
Why?
| | Dexamethasone | 2 | 2019 | 365 | 0.180 |
Why?
| | Forced Expiratory Volume | 4 | 2015 | 450 | 0.180 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 153 | 0.180 |
Why?
| | Motivational Interviewing | 1 | 2023 | 121 | 0.180 |
Why?
| | Child, Hospitalized | 2 | 2020 | 54 | 0.180 |
Why?
| | Oscillometry | 2 | 2011 | 35 | 0.170 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2021 | 35 | 0.160 |
Why?
| | Information Systems | 1 | 2021 | 56 | 0.160 |
Why?
| | Hospitals, Pediatric | 3 | 2019 | 558 | 0.160 |
Why?
| | Electronic Health Records | 2 | 2021 | 1196 | 0.160 |
Why?
| | Sample Size | 1 | 2010 | 121 | 0.160 |
Why?
| | Parents | 4 | 2021 | 1403 | 0.140 |
Why?
| | Infant | 11 | 2022 | 10077 | 0.140 |
Why?
| | Azithromycin | 1 | 2018 | 101 | 0.130 |
Why?
| | Bronchoscopy | 2 | 2016 | 227 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2011 | 1061 | 0.110 |
Why?
| | Macrophages | 1 | 2002 | 1507 | 0.100 |
Why?
| | Child | 12 | 2023 | 22707 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2018 | 578 | 0.100 |
Why?
| | Pseudomonas aeruginosa | 2 | 2018 | 395 | 0.100 |
Why?
| | Asthma | 2 | 2019 | 1797 | 0.090 |
Why?
| | Hyperplasia | 1 | 2012 | 177 | 0.090 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 43 | 0.090 |
Why?
| | Male | 16 | 2023 | 72842 | 0.090 |
Why?
| | Humans | 21 | 2023 | 145474 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2012 | 5904 | 0.080 |
Why?
| | Colorado | 3 | 2020 | 4553 | 0.080 |
Why?
| | Patient Readmission | 1 | 2016 | 769 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2011 | 1111 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1371 | 0.080 |
Why?
| | Smoking Prevention | 2 | 2021 | 166 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1923 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2013 | 2953 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1997 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2013 | 3413 | 0.070 |
Why?
| | Smoking | 3 | 2021 | 1472 | 0.070 |
Why?
| | Female | 14 | 2023 | 78844 | 0.070 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 371 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2012 | 5423 | 0.060 |
Why?
| | Inpatients | 2 | 2022 | 553 | 0.060 |
Why?
| | Administration, Inhalation | 3 | 2018 | 571 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2018 | 2062 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2011 | 3623 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2008 | 531 | 0.050 |
Why?
| | Caregivers | 2 | 2023 | 1073 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2016 | 2970 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22529 | 0.050 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2002 | 23 | 0.050 |
Why?
| | Chromones | 1 | 2002 | 43 | 0.050 |
Why?
| | Osmotic Pressure | 1 | 2002 | 41 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 254 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 126 | 0.040 |
Why?
| | Beclomethasone | 1 | 2001 | 8 | 0.040 |
Why?
| | Flavonoids | 1 | 2002 | 85 | 0.040 |
Why?
| | Morpholines | 1 | 2002 | 130 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 171 | 0.040 |
Why?
| | Adrenal Glands | 1 | 2001 | 76 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 264 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2002 | 288 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 782 | 0.040 |
Why?
| | Recurrence | 2 | 2018 | 1138 | 0.040 |
Why?
| | Cohort Studies | 1 | 2011 | 6013 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2021 | 318 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2001 | 269 | 0.040 |
Why?
| | Counseling | 1 | 2023 | 400 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 307 | 0.040 |
Why?
| | Tobacco Use | 1 | 2020 | 62 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2002 | 440 | 0.040 |
Why?
| | Pulmonologists | 1 | 2019 | 14 | 0.040 |
Why?
| | Vital Capacity | 1 | 2010 | 292 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2019 | 37 | 0.040 |
Why?
| | Cell Survival | 1 | 2002 | 1100 | 0.040 |
Why?
| | Drug Substitution | 1 | 2019 | 63 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 624 | 0.040 |
Why?
| | Reference Values | 1 | 2010 | 798 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 820 | 0.040 |
Why?
| | Directive Counseling | 1 | 2018 | 45 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2001 | 506 | 0.030 |
Why?
| | Tobramycin | 1 | 2018 | 63 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2016 | 17291 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2001 | 477 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 1217 | 0.030 |
Why?
| | Consensus | 1 | 2019 | 477 | 0.030 |
Why?
| | Family | 1 | 2022 | 682 | 0.030 |
Why?
| | Pneumonia | 1 | 2002 | 636 | 0.030 |
Why?
| | Treatment Outcome | 4 | 2018 | 11772 | 0.030 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.030 |
Why?
| | Prospective Studies | 4 | 2012 | 8057 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1044 | 0.030 |
Why?
| | Pediatrics | 1 | 2023 | 1121 | 0.030 |
Why?
| | Hospitalists | 1 | 2019 | 267 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 870 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2002 | 4148 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2008 | 428 | 0.030 |
Why?
| | Social Support | 1 | 2018 | 646 | 0.030 |
Why?
| | Apoptosis | 1 | 2002 | 2440 | 0.020 |
Why?
| | Functional Residual Capacity | 1 | 2013 | 7 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2001 | 2803 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2012 | 42 | 0.020 |
Why?
| | Emergency Service, Hospital | 2 | 2019 | 2381 | 0.020 |
Why?
| | Young Adult | 2 | 2020 | 14218 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 172 | 0.020 |
Why?
| | Adult | 3 | 2020 | 40777 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3342 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 202 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2930 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1243 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2022 | 6447 | 0.020 |
Why?
| | United States | 2 | 2021 | 16098 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 2013 | 451 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2013 | 391 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2460 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 971 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2010 | 8333 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 7123 | 0.020 |
Why?
| | Quality Improvement | 1 | 2016 | 1295 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 36215 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 527 | 0.020 |
Why?
| | Administration, Oral | 1 | 2008 | 866 | 0.010 |
Why?
| | Mice | 1 | 2002 | 18329 | 0.010 |
Why?
| | Airway Resistance | 1 | 2001 | 38 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 10885 | 0.010 |
Why?
| | Nebulizers and Vaporizers | 1 | 2001 | 62 | 0.010 |
Why?
| | Probability | 1 | 2001 | 307 | 0.010 |
Why?
| | Aged | 1 | 2010 | 26153 | 0.010 |
Why?
| | Animals | 1 | 2002 | 38030 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2001 | 638 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2001 | 1300 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2028 | 0.010 |
Why?
| | Pilot Projects | 1 | 2001 | 1891 | 0.010 |
Why?
|
|
Kerby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|